United Therapeutics plunges 33% as oral PAH drug misses Ph III endpoint, filing delay likely
US drugmaker United Therapeutics says that a late-stage pulmonary arterial hypertension trial of oral treprostinil failed to meet its primary endpoint.
The product, which is a sustained-release formulation of a UT drug already approved for dosing via infusion and injection, did not achieve significance for six-minute walk distance at week-16.
On the day of the news, November 17, shares in the Maryland-based company plummetted 32.9% to $60.74 in afternoon trading. Earlier in the session they fell to a 12-month low of $56.29.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze